Anti-fibrotic medications, such as Esbriet (pirfenidone) and Ofev (nintedanib), are not cost-effective treatments for idiopathic pulmonary fibrosis (IPF) in the U.S. due to their high prices, even though they remain the only effective therapies, according to a recent study. The study, “Cost-effectiveness of the anti-fibrotics for…
News
Injuries to the lung from diseases like idiopathic pulmonary fibrosis (IPF) can trigger an abnormal cell response that affects lung cell repair and is associated with excessive tissue scarring, a study showed. Scientists noted that further studies are needed to determine whether this process is reversible, which may lead…
Patients with idiopathic pulmonary fibrosis (IPF) with chronic cough who are being treated with the investigational oral medication NP-120 (ifenprodil) in a small clinical trial tended to experience a reduction in coughing, according to the therapy’s developer Algernon Pharmaceuticals. The company is funding an open-label Phase 2…
Cudetaxestat (BLD-0409), an experimental medication for idiopathic pulmonary fibrosis (IPF) from Blade Therapeutics, was well-tolerated among healthy volunteers when given in combination with other IPF treatments — specifically nintedanib and pirfenidone — in a Phase 1 study. “These findings provide confidence in the potential to safely co-administer cudetaxestat…
Enrollment has been completed for INTEGRIS-IPF, a Phase 2a trial testing PLN-74809, an experimental oral anti-fibrotic therapy, in people with idiopathic pulmonary fibrosis (IPF). Pliant Therapeutics, the company developing PLN-74809 and sponsoring the trial, said it is expecting top-line results to become available midway through the year. The…
Lab-made versions of naturally occurring forms of nitro oleic acid effectively treated established pulmonary fibrosis (PF) in a mouse model, a study reports. These findings support the further development of these agents for reversing fibrosis, or tissue scarring, in the lungs and other organs, its scientists noted. The study,…
About half of the healthy older adults given PureTech’s anti-fibrotic therapy LYT-100 (deupirfenidone) were less likely to report gastrointestinal (GI) side effects compared with those given Esbriet (pirfenidone), according to a recent crossover study. Based on these findings, data to date from LYT-100’s clinical program and regulatory feedback, the…
MannKind Corporation has extended its collaboration with Thirona Bio to continue work toward an inhaled therapy for fibrotic diseases affecting the lungs, including idiopathic pulmonary fibrosis (IPF). Under a collaboration established last year, the companies are evaluating the therapeutic potential of FBM5712, an investigational medicine designed to…
If left untreated by anti-fibrotic medications, idiopathic pulmonary fibrosis (IPF) has a 50% mortality rate after three years, according to a recent observational study using real-world data. This is compared with a 26–31% mortality rate among IPF patients taking available anti-fibrotics, such as Esbriet (pirfenidone) and Ofev…
Treatment with either Ofev (nintedanib) or Esbriet (pirfenidone) — both antifibrotic therapies, but with different mechanisms of action — “offers protection” and can slow lung function decline in people with pulmonary fibrosis (PF), according to a new analysis. Moreover, the results showed that these medications can significantly reduce…
